+

HUP9903673A3 - Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc - Google Patents

Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc

Info

Publication number
HUP9903673A3
HUP9903673A3 HU9903673A HUP9903673A HUP9903673A3 HU P9903673 A3 HUP9903673 A3 HU P9903673A3 HU 9903673 A HU9903673 A HU 9903673A HU P9903673 A HUP9903673 A HU P9903673A HU P9903673 A3 HUP9903673 A3 HU P9903673A3
Authority
HU
Hungary
Prior art keywords
azt
hiv
alone
treatment
combination
Prior art date
Application number
HU9903673A
Other languages
English (en)
Original Assignee
Vertex Pharmaceuticals Inc Cam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc Cam filed Critical Vertex Pharmaceuticals Inc Cam
Publication of HUP9903673A2 publication Critical patent/HUP9903673A2/hu
Publication of HUP9903673A3 publication Critical patent/HUP9903673A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HU9903673A 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc HUP9903673A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/567,199 US5646180A (en) 1995-12-05 1995-12-05 Treatment of the CNS effects of HIV
PCT/US1996/019447 WO1997020554A1 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478, alone or in combination with azt or 3tc

Publications (2)

Publication Number Publication Date
HUP9903673A2 HUP9903673A2 (hu) 2000-03-28
HUP9903673A3 true HUP9903673A3 (en) 2000-08-28

Family

ID=24266147

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903673A HUP9903673A3 (en) 1995-12-05 1996-12-05 Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc

Country Status (23)

Country Link
US (1) US5646180A (hu)
EP (1) EP0866696B1 (hu)
JP (1) JP2000501713A (hu)
KR (1) KR19990071750A (hu)
CN (1) CN1203530A (hu)
AP (1) AP864A (hu)
AT (1) ATE279922T1 (hu)
AU (1) AU722850B2 (hu)
BR (1) BR9611861A (hu)
CA (1) CA2238471A1 (hu)
CZ (1) CZ291994B6 (hu)
DE (1) DE69633680T2 (hu)
ES (1) ES2231828T3 (hu)
HU (1) HUP9903673A3 (hu)
NO (1) NO317837B1 (hu)
NZ (1) NZ324603A (hu)
OA (1) OA10691A (hu)
PL (1) PL187747B1 (hu)
PT (1) PT866696E (hu)
RU (1) RU2203658C2 (hu)
UA (1) UA61902C2 (hu)
WO (1) WO1997020554A1 (hu)
ZA (1) ZA9610139B (hu)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107499A (en) * 1988-02-26 2000-08-22 Neuromedica, Inc. Dopamine analog amide
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
JP2000515852A (ja) * 1996-06-25 2000-11-28 グラクソ、グループ、リミテッド Ｈｉｖの治療に使用するためのｖｘ４７８、ジドブジン、ｆｔｃおよび／または３ｔｃを含んでなる組合わせ
WO1997049410A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
JP2001525840A (ja) * 1997-05-17 2001-12-11 グラクソ、グループ、リミテッド 炭素環式ヌクレオシド１５９２ｕ８９を含有する抗ウイルス的組合せ
AU8145198A (en) * 1997-06-16 1999-01-04 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US6576231B2 (en) * 1997-09-12 2003-06-10 Schering Ag Methods for treating HIV-Infected Patients by the Administration of GM-CSF and a protease inhibitor
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6309632B1 (en) * 1998-04-28 2001-10-30 Immunex Corporation Methods for treating HIV-infected patients by administering GM-CSF
US20090197827A1 (en) * 1998-05-29 2009-08-06 Dunn Ben M Combination Therapy for Treatment of FIV Infection
US6875773B1 (en) * 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
US7235583B1 (en) * 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
DE60026568D1 (de) 1999-12-21 2006-05-04 Mgi Gp Inc Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
DE60112318D1 (de) * 2000-10-16 2005-09-01 Conor Medsystems Inc Expandierbare medizinische vorrichtung zum zuführen eines heilmittels
EP1423107B1 (en) * 2001-03-23 2012-05-09 Luitpold Pharmaceuticals, Inc. Fatty alcohol drug conjugates
WO2002076402A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
DK1778251T3 (da) 2004-07-27 2011-07-18 Gilead Sciences Inc Nukleosidphosphatkonjugater som anti-HIV-midler
EP1845969A4 (en) * 2005-01-20 2010-04-28 Univ Rochester COMPOSITIONS AND METHODS RELATED TO MITOCHONDRIA HYPERPOLARIZATION IN NEUROLOGICAL DISEASES
WO2007076372A2 (en) * 2005-12-23 2007-07-05 University Of Rochester Treatment of neuroaids using inhibitors of glycogen synthase kinase (gsk)-3
TW200812961A (en) * 2006-04-19 2008-03-16 Abbott Gmbh & Co Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US9789012B2 (en) 2014-02-28 2017-10-17 Attends Healthcare Products, Inc. Absorbent article with multi-layer folded absorbent core
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN106714800B (zh) 2014-07-11 2021-09-03 吉利德科学公司 用于治疗hiv的toll样受体调节剂
US20180263985A1 (en) 2015-09-15 2018-09-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
WO2019231926A1 (en) 2018-05-28 2019-12-05 Attends Healthcare Products, Inc. Dryness layer laminate for absorbent articles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
WO1994013629A1 (en) * 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease

Also Published As

Publication number Publication date
US5646180A (en) 1997-07-08
AP9801340A0 (en) 1998-09-30
OA10691A (en) 2001-05-04
KR19990071750A (ko) 1999-09-27
ZA9610139B (en) 1997-06-17
DE69633680T2 (de) 2006-02-23
CA2238471A1 (en) 1997-06-12
NO317837B1 (no) 2004-12-20
PT866696E (pt) 2005-03-31
CN1203530A (zh) 1998-12-30
AU1148697A (en) 1997-06-27
DE69633680D1 (de) 2004-11-25
NO982556L (no) 1998-06-04
CZ291994B6 (cs) 2003-07-16
AP864A (en) 2000-08-11
HUP9903673A2 (hu) 2000-03-28
ES2231828T3 (es) 2005-05-16
PL327061A1 (en) 1998-11-23
NO982556D0 (no) 1998-06-04
WO1997020554A1 (en) 1997-06-12
ATE279922T1 (de) 2004-11-15
PL187747B1 (pl) 2004-09-30
RU2203658C2 (ru) 2003-05-10
JP2000501713A (ja) 2000-02-15
NZ324603A (en) 2000-08-25
UA61902C2 (en) 2003-12-15
EP0866696B1 (en) 2004-10-20
CZ170898A3 (cs) 1998-09-16
EP0866696A1 (en) 1998-09-30
AU722850B2 (en) 2000-08-10
BR9611861A (pt) 1999-05-18

Similar Documents

Publication Publication Date Title
HUP9903673A3 (en) Treatment of the cns effects of hiv with vx-478,alone or in combination with azt or 3tc
GR3031226T3 (en) Body conforming absorbent article.
AU6924796A (en) 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c
IL110208A0 (en) Doubled haploids
HUP9903249A3 (en) Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
DK0721522T3 (da) Iriserende stoffer.
AU2418499A (en) Org-5222 in the treatment of depression
HK1004659A1 (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
HU9903098D0 (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
EP1032266A4 (en) USE OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION IN THE TREATMENT OF ARTHRITIS
GB9424005D0 (en) Infra-red body
AU2325695A (en) The wave rider body suit
EP0684004A3 (de) Sanitärgegenstand.
GB9415921D0 (en) Infra-red body
NO307542B1 (no) Kasseformet legeme, særlig postkasse, samt front til samme
EP0631937A3 (en) Box-shaped body and its construction.
FR2697913B3 (fr) Microéprouvette comportant des organes accroissant la surface.
PL304504A1 (en) Desktop or the like
GB9825969D0 (en) Agents useful in the treatment of reproductive disorders
AUPO922297A0 (en) Disulphide useful in the treatment of cardiovascular diseases
AU657882B2 (en) Improvements in or relating to the treatment of diarrhoea
GB9506149D0 (en) The body people
AUPN000894A0 (en) The bath
CA65516S (en) Snowmobile suit or the like
ES1028780Y (es) Tabla de buceo por arrastre.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载